CliffBio
small molecule

ZOLADEX

GOSERELIN ACETATE

Loss of exclusivity—loss of exclusivity
CompanyTersera Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameZOLADEX
Active ingredientGOSERELIN ACETATE
StrengthEQ 10.8MG BASE
Dosage formIMPLANT
RouteIMPLANTATION
ModalitySmall molecule
FDA approvalJanuary 1996
Marketing statusRX

More from Tersera Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ZOLADEX patent cliff — loss of exclusivity — | CliffBio